Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Sports
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
AtriCure
(NASDAQ:ATRC)
Intraday
$30.42
0.28
[0.93%]
After-Hours
$30.42
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$30.42
0.28
[0.93%]
At close: Mar 28
$30.42
0
[0.00%]
After Hours: 4:00PM EDT
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for AtriCure Stock (NASDAQ:ATRC)
AtriCure Stock (NASDAQ: ATRC)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, February 16, 2024
Coinbase To Rally Around 45%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
-
Feb 16, 2024, 8:30AM
Cracking The Code: Understanding Analyst Reviews For AtriCure
Benzinga Insights
-
Feb 16, 2024, 7:00AM
Needham Maintains Buy on AtriCure, Raises Price Target to $46
Benzinga Newsdesk
-
Feb 16, 2024, 5:41AM
Thursday, February 15, 2024
Recap: AtriCure Q4 Earnings
Benzinga Insights
-
Feb 15, 2024, 4:05PM
AtriCure Q4 2023 Adj EPS $(0.21) Beats $(0.23) Estimate, Sales $106.50M Beat $103.68M Estimate
Benzinga Newsdesk
-
Feb 15, 2024, 4:03PM
Earnings Scheduled For February 15, 2024
Benzinga Insights
-
Feb 15, 2024, 5:17AM
Wednesday, February 14, 2024
AtriCure's Earnings: A Preview
Benzinga Insights
-
Feb 14, 2024, 10:01AM
Thursday, January 18, 2024
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights
-
Jan 18, 2024, 8:05AM
Thursday, January 04, 2024
Key Takeaways From AtriCure Analyst Ratings
Benzinga Insights
-
Jan 4, 2024, 7:00AM
Needham Maintains Buy on AtriCure, Lowers Price Target to $44
Benzinga Newsdesk
-
Jan 4, 2024, 6:27AM
Wednesday, November 29, 2023
JMP Securities Reiterates Market Outperform on AtriCure, Maintains $60 Price Target
Benzinga Newsdesk
-
Nov 29, 2023, 10:45AM
Where AtriCure Stands With Analysts
Benzinga Insights
-
Nov 29, 2023, 7:00AM
Needham Reiterates Buy on AtriCure, Maintains $49 Price Target
Benzinga Newsdesk
-
Nov 29, 2023, 4:31AM
Tuesday, November 28, 2023
Needham Says Medtronic Initiation Of Limited US Release Of Left Atrial Appendage Exclusion System Could Create Overhang For AtriCure
Benzinga Newsdesk
-
Nov 28, 2023, 2:32PM
Thursday, November 02, 2023
JP Morgan Maintains Overweight on AtriCure, Lowers Price Target to $50
Benzinga Newsdesk
-
Nov 2, 2023, 5:27PM
Needham Maintains Buy on AtriCure, Lowers Price Target to $49
Benzinga Newsdesk
-
Nov 2, 2023, 6:32AM
Wednesday, November 01, 2023
AtriCure Sees FY23 Adj. EPS $(0.76)-$(0.74) Vs $(0.92) Est.; Revenue $394M-$396M Vs $393.87M Est.
Benzinga Newsdesk
-
Nov 1, 2023, 5:49PM
AtriCure Q3 2023 Adj EPS $(0.20) Beats $(0.31) Estimate, Sales $98.29M Beat $96.73M Estimate
Benzinga Newsdesk
-
Nov 1, 2023, 4:13PM
Earnings Scheduled For November 1, 2023
Benzinga Insights
-
Nov 1, 2023, 7:19AM
Monday, October 23, 2023
JMP Securities Initiates Coverage On AtriCure with Market Outperform Rating, Announces Price Target of $60
Benzinga Newsdesk
-
Oct 23, 2023, 6:00AM
Friday, September 29, 2023
UBS Initiates Coverage On AtriCure with Buy Rating, Announces Price Target of $56
Benzinga Newsdesk
-
Sep 29, 2023, 11:38AM
Wednesday, July 26, 2023
Needham Maintains Buy on AtriCure, Raises Price Target to $68
Benzinga Newsdesk
-
Jul 26, 2023, 5:49AM
Tuesday, July 25, 2023
AtriCure Raises FY23 Adjusted Loss Per Share Outlook From $(1.10)-$(1.15) To $(0.92)-$(0.94), Consensus $(1.02)
Benzinga Newsdesk
-
Jul 25, 2023, 4:32PM
AtriCure Sees FY23 Adj EPS $(0.94)-$(0.92) Vs $(1.02) Est
Benzinga Newsdesk
-
Jul 25, 2023, 4:30PM
AtriCure Boosts FY23 Revenue Forecast From $385M-$392M To $392M-$395M, Consensus $388.31M
Benzinga Newsdesk
-
Jul 25, 2023, 4:29PM
AtriCure Sees FY23 Revenue $392M-$395M Vs $388.31M Est
Benzinga Newsdesk
-
Jul 25, 2023, 4:28PM
AtriCure Q2 Adj EPS $(0.12) Beats $(0.29) Estimate, Sales $100.92M Beat $97.49M Estimate
Benzinga Newsdesk
-
Jul 25, 2023, 4:09PM
Earnings Scheduled For July 25, 2023
Benzinga Insights
-
Jul 25, 2023, 5:00AM
Friday, June 02, 2023
Needham Reiterates Buy on AtriCure, Maintains $60 Price Target
Benzinga Newsdesk
-
Jun 2, 2023, 5:15AM
Wednesday, May 24, 2023
New Data Out Of Cleveland Clinic Shows BioSig PURE EP May Be Used For More Precise Approach For $6 Billion Annual Atrial Fibrillation Market
Rachael Green
-
May 24, 2023, 8:00AM
Wednesday, May 03, 2023
AtriCure shares are trading higher after the company reported better-than-expected Q1 results.
Benzinga Newsdesk
-
May 3, 2023, 12:26PM
What 7 Analyst Ratings Have To Say About AtriCure
Benzinga Insights
-
May 3, 2023, 9:01AM
Needham Maintains Buy on AtriCure, Raises Price Target to $60
Benzinga Newsdesk
-
May 3, 2023, 5:58AM
Tuesday, May 02, 2023
AtriCure Q1 EPS $(0.23) Beats $(0.34) Estimate, Sales $93.49M Beat $87.53M Estimate
Benzinga Newsdesk
-
May 2, 2023, 4:08PM
Monday, April 17, 2023
Needham Maintains Buy on AtriCure, Maintains $58 Price Target
Benzinga Newsdesk
-
Apr 17, 2023, 6:13PM
Thursday, March 16, 2023
AtriCure Board Member Awarded $393K Worth of Stock Options
Benzinga Insights
-
Mar 16, 2023, 11:02AM
Wednesday, February 22, 2023
BTIG Maintains Buy on AtriCure, Lowers Price Target to $55
Benzinga Newsdesk
-
Feb 22, 2023, 9:35AM
Analyst Ratings for AtriCure
Benzinga Insights
-
Feb 22, 2023, 9:01AM
Stifel Maintains Buy on AtriCure, Lowers Price Target to $48
Benzinga Newsdesk
-
Feb 22, 2023, 8:44AM
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $74
Benzinga Newsdesk
-
Feb 22, 2023, 8:32AM
Needham Reiterates Buy on AtriCure, Maintains $58 Price Target
Benzinga Newsdesk
-
Feb 22, 2023, 5:42AM
Tuesday, February 21, 2023
AtriCure Q4 EPS $(0.09) Beats $(0.18) Estimate, Sales $88.03M Beat $87.66M Estimate
Benzinga Newsdesk
-
Feb 21, 2023, 4:11PM
Earnings Scheduled For February 21, 2023
Benzinga Insights
-
Feb 21, 2023, 5:20AM
Monday, February 20, 2023
Earnings Outlook For AtriCure
Benzinga Insights
-
Feb 20, 2023, 10:00AM
Monday, February 06, 2023
Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $81
Benzinga Newsdesk
-
Feb 6, 2023, 8:08AM
Tuesday, January 31, 2023
AtriCure Announces First Patient Treated In The LeAAPS Clinical Trial
Bill Haddad
-
Jan 31, 2023, 8:02AM
Monday, January 09, 2023
AtriCure Sees Q4 Sales ~$88M Vs. $87.66M Est., Sees FY22 Sales ~$330.4M Vs. $330.06M Est.
Benzinga Newsdesk
-
Jan 9, 2023, 8:19AM
Monday, December 19, 2022
Moderna To Rally Over 42%? Here Are 10 Other Price Target Changes For Monday
Lisa Levin
-
Dec 19, 2022, 8:29AM
Needham Maintains Buy on AtriCure, Raises Price Target to $58
Benzinga Newsdesk
-
Dec 19, 2022, 5:46AM
Wednesday, November 02, 2022
Canaccord Genuity Maintains Buy on AtriCure, Lowers Price Target to $65
Benzinga Newsdesk
-
Nov 2, 2022, 10:14AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch